Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins

Viral Immunology

Volumn 23, Issue 2, 2010, Pages 169-180

  Nayak, Jennifer L ^a,b   Richards, Katherine A ^a   Chaves, Francisco A ^a   Sant, Andrea J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; INFLUENZA VIRUS A H1N1; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; VIRUS STRAIN;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED C57BL; PEPTIDES; SPLEEN; T-CELL ANTIGEN RECEPTOR SPECIFICITY; VIRAL PROTEINS;

MUS; ORTHOMYXOVIRIDAE;

EID: 77953957400     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0099     Document Type: Article

References (67)

1. World Health Organization: New WHO influenza vaccine recommendations for 2005-2006 season, northern hemisphere. Euro Surveill 2005;10:E050217-E050211.
2. American Academy of Pediatrics: Prevention of influenza: recommendations for influenza immunization of children, 2007-2008. Pediatrics 2008;121:e1016-e1031.
3. Centers for Disease Control and Prevention: Influenza vaccination coverage among children and adults-United States, 2008-2009 influenza season. MMWR Morb Mortal Wkly Rep 2009;58:1091-1095.
4. Centers for Disease Control and Prevention: Serum crossreactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009;58:521-524.
5. Anthony DD, and Lehmann PV: T-cell epitope mapping using the ELISPOT approach. Methods 2003;29:260-269.
6. Belz GT, Stevenson PG, and Doherty PC: Contemporary analysis of MHC-related immunodominance hierarchies in the CD8 T cell response to influenza A viruses. J Immunol 2000;165:2404-2409.
7. Belz GT, Xie W, Altman JD, and Doherty PC: A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J Virol 2000;74:3486-3493.
8. Belz, GT, Wodarz D, Diaz G, et al.: Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-celldeficient mice. J. Virol. 76:12388-12393.
9. Boulo S, Akarsu H, Ruigrok RWH, and Baudin F: Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res 2007;124:12-21.
10. Brown DM, Román E, and Swain SL: CD4 T cell responses to influenza infection. Semin Immunol 2004;16:171-177.
11. Brown DM, Dilzer AM, Meents DL, and Swain SL: CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 2006;177:2888-2898.
12. Busch R, Rinderknecht CH, Roh S, et al.: Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol Rev 2005;207: 242-260.
13. Chicz RM, Urban RG, Gorga JC, et al.: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
14. Crotzer VL, and Blum JS: Cytosol to lysosome transport of intracellular antigens during immune surveillance. Traffic 2008;9:10-16.
15. Crowe SR, Miller SC, Brown DM, et al.: Uneven distribution of MHC class II epitopes within the influenza virus. Vaccine 2006;24:457-467.
16. Crowe SR, Miller SC, and Woodland DL: Identification of protective and non-protective T cell epitopes in influenza. Vaccine 2006;24:452-456.
17. Dawood FS, Jain S, Finelli L, et al.: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-2615.
18. Doherty PC, Topham DJ, Tripp RA, et al.: Effector CD4 and CD8 T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997;159:105-117.
19. Doherty PC, Turner SJ, Webby RG, and Thomas PG: Influenza and the challenge for immunology. Nat Immunol 2006;7:449-455.
20. Dongre AR, Kovats S, deRoos P, et al.: In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol 2001;31:1485-1494.
21. Geginat G, Schenk S, Skoberne M, et al.: A novel approach of direct ex vivo epitope mapping identifies dominant and subdominant CD4 and CD8 T cell epitopes from Listeria monocytogenes. J Immunol 2001;166:1877-1884.
22. Gerdil C: The annual production cycle for influenza vaccine. Vaccine 2003;21:1776-1779.
23. Hale BG, Randall RE, Ort?́n J, and Jackson D: The multifunctional NS1 protein of influenza A viruses. J Gen Virol 2008;89:2359-2376.
24. Hunt DF, Michel H, Dickinson TA, et al.: Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992;256: 1817-1820.
25. Hussell T, and Cavanagh MM: The innate immune rheostat: influence on lung inflammatory disease and secondary bacterial pneumonia. Biochem Soc Trans 2009;37:811-813.
26. Itoh Y, Shinya K, Kiso M, et al.: In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009;460:1021-1025.
27. Jane-wit D, Yu M, Edling AE, et al.: A novel class II-binding motif selects peptides that mediate organ-specific autoimmune disease in SWXJ, SJL=J, and SWR=J mice. J Immunol 2002;169:6507-6514.
28. Kalbus M, Fleckenstein BT, Offenhäusser M, et al.: Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-A(s). Eur J Immunol 2001;31:551-562.
29. Karlsson AC, Martin JN, Younger SR, et al.: Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003;283:141-153.
30. Karp DR, Teletski CL, Jaraquemada D, et al.: Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. J Exp Med 1990;171:615-628.
31. Kohlmeier JE, and Woodland DL: Immunity to respiratory viruses. Annu Rev Immunol 2009;27:61-82.
32. Lazarski CA, Chaves FA, Jenks SA, et al.: The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 2005;23: 29-40.
33. Lazarski CA, Chaves FA, and Sant AJ: The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability. J Exp Med 2006;203:1319-1328.
34. Lee HK, and Iwasaki A: Autophagy and antiviral immunity. Curr Opin Immunol 2008;20:23-29.
35. Lewis DB: Avian flu to human influenza. Annu Rev Med 2006;57:139-154.
36. Li P, Gregg JL, Wang N, et al.: Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. Immunol Rev 2005;207:206-217.
37. Liu X, Dai S, Crawford F, et al.: Alternate interactions define the binding of peptides to the MHC molecule IA(b). Proc Natl Acad Sci USA 2002;99:8820-8825.
38. Loss GE, Elias CG, Fields PE, et al.: Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J Exp Med 1993;178:73-85.
39. McGill J, Heusel JW, and Legge KL: Innate immune control and regulation of influenza virus infections. J Leukoc Biol 2009;86:803-812.
40. McMurry JA, Johansson BE, and De Groot AS: A call to cellular humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Human Vaccines 2008;4:148-157.
41. Münz C: Enhancing immunity through autophagy. Annu Rev Immunol 2009;27:423-449.
42. Nayak DP, Hui EK, and Barman S: Assembly and budding of influenza virus. Virus Res 2004;106:147-165.
43. Nayak, DP, Balogun RA, Yamada H, et al.: Influenza virus morphogenesis and budding. Virus Res 2009;143:147-161.
44. Nielsen M, and Lund O: NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009;10:296-306.
45. Peiris JS, Poon LL, and Guan Y: Emergence of a novel swineorigin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009;45:169-173.
46. Richards KA, Chaves FA, Krafcik FR, et al.: Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin. J Virol 2007;81:7608-7619.
47. Richards KA, Chaves FA, and Sant AJ: Infection of HLADR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. J Virol 2009;83:6566-6577.
48. Robinson JH, and Delvig AA: Diversity in MHC class II antigen presentation. Immunology 2002;105:252-262.
49. Rollini P, Mach B, and Gorski J: Linkage map of three HLADR beta-chain genes: evidence for a recent duplication event. Proc Natl Acad Sci USA 1985;82:7197-7201.
50. Sant AJ, Beeson C, McFarland B, et al.: Individual hydrogen bonds play a critical role in MHC class II:peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange. Immunol Rev 1999;172:239-253.
51. Sant AJ, Chaves FA, Jenks SA, et al.: The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol Rev 2005;207:261-278.
52. Sant AJ, Chaves FA, Krafcik FR, et al.: Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev Vaccines 2007;6:357-368.
53. Sette A, Southwood S, Miller J, and Appella E: Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 1995;181:677-683.
54. Sette A, Moutaftsi M, Moyron-Quiroz J, et al.: Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008;28:847-858.
55. Stern LJ, and Calvo-Calle JM: HLA-DR: molecular insights and vaccine design. Curr Pharm Des 2009;15:3249-3261.
56. Sun JC, MA Williams, MJ Bevan 2004 CD4 T cells are required for the maintenance, not programming, of memory CD8 T cells after acute infection. Nat. Immunol. 5:927-933.
57. Swain SL, Agrewala JN, Brown DM, et al.: CD4 T-cell memory: generation and multi-faceted roles for CD4 T cells in protective immunity to influenza. Immunol Rev 2006;211:8-22.
58. Tamura S-I, and Kurata T: Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004;57:236-247.
59. Thomas PG, Keating R, Hulse-Post DJ, and Doherty PC: Cell-mediated protection in influenza infection. Emerg Infect Dis 2006;12:48-54.
60. Thompson WW, Shay DK, Weintraub E, et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-186. (Pubitemid 36068705)
61. Thompson WW, Shay DK, Weintraub E, et al.: Influenzaassociated hospitalizations in the United States. JAMA 2004; 292:1333-1340.
62. Tobery TW: A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. J Immunol Methods 2001;254:59-66.
63. Tobery TW, and Caulfield MJ: Identification of T-cell epitopes using ELISpot and peptide pool arrays. Methods Mol Med 2004;94:121-132.
64. Weiss S, and Bogen B: MHC class II-restricted presentation of intracellular antigen. Cell 1991;64:767-776.
65. Yewdell JW, and Bennink JR: Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999;17:51-88.
66. Zhong W, Reche PA, Lai C-C, et al.: Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J Biological Chem 2003;278:45135-45144.
67. Zhu Y, Rudensky AY, Corper AL, et al.: Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif. J Mol Biol 2003;326:1157-1174.